Novocure: A Mispriced Cash-Generating Biotech With Upside Potential (NASDAQ:NVCR)
· seekingalpha.com
Novocure (NVCR) looks undervalued: 16% YoY revenue growth, low EV/Sales, and Optune launches could drive upside.
NovoCure ( NVCR ) is a mid-sized biotechnology company focused on cancer treatments . NovoCure currently has 10 clinical trials across multiple CNS and torso in...